ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Low dose Strep A AS37

A development code. Also written as “Medium dose Strep A AS37” and “High dose Strep A AS37”.

Its studies are mostly in Streptococcal Infections, led by GlaxoSmithKline.

Furthest: phase 1, since Jul 11, 20251 company-led study, 1 open or runningNext primary completion: Jun 29, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 1since Jul 11, 2025Jul 11, 2025Jun 29, 2027phase 1 · NCT07085702

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 11, 2025First study: phase 1 study in Streptococcal InfectionsFirst studyNCT07085702 · 108 planned · Australia

Ahead

  1. Jun 29, 2027Primary completion: phase 1 study in Streptococcal InfectionsNCT07085702

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07085702Streptococcal Infections · Australia1RecruitingJun 29, 2027108

How it is read

Names in the registry

  • “Low dose Strep A AS37”, 1 entry
  • “Medium dose Strep A AS37”, 1 entry
  • “High dose Strep A AS37”, 1 entry

Codes read as this program: AS37.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.